Advanced search
1 file | 1.18 MB

Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients

Virginie Mortier (UGent) , Kenny Dauwe (UGent) , Leen Vancoillie (UGent) , Delfien Staelens (UGent) , Filip Van Wanzeele (UGent) , Dirk Vogelaers (UGent) , Linos Vandekerckhove (UGent) , Kristen Chalmet (UGent) and Chris Verhofstede (UGent)
(2013) PLOS ONE. 8(11).
Author
Organization
Abstract
Background: Determination of HIV-1 co-receptor use is a necessity before initiation of a CCR5 antagonist but the longevity of a CCR5-use prediction remains unknown. Methods: Genotypic co-receptor tropism determination was performed in 225 newly diagnosed individuals consulting an AIDS Reference Centre. Samples were collected at diagnosis and at initiation of antiretroviral therapy or just before closure of the study for patients who did not initiate therapy. For individuals with a discordant tropism prediction on the two longitudinal samples, analysis of intermediate samples and single genome sequencing of proviral DNA was performed to confirm the tropism switch. Deep sequencing was done to identify minor CXCR4 or CCR5-using populations in the initial sample. Results: Overall, tropism switches were rare (7.6%). Only a geno2pheno false positive rate of <50% at baseline was retained as predictive for a subsequent switch from CCR5-use only to predicted CXCR4-use. Minor CXCR4-using virus populations were detected in the first sample of 9 of the 14 R5-to-X4 switchers but the subsequent outgrowth of these minor populations was documented in only 3. Conclusions: With the current guidelines for treatment initiation at CD4(+) T cell counts of <500 cells/mm(3), co-receptor switch between diagnosis and starting antiretroviral therapy is rare. Patients with R5 viruses and a geno2pheno FPR of <50% are more prone to subsequent co-receptor switch than patients with an FPR of >50% and will need repeat tropism testing if initiation of maraviroc is considered and previous testing dates from more than a year before.
Keywords
TROPISM, PROGNOSTIC VALUE, USAGE, AIDS, INTERACTIVE TREE, HUMAN-IMMUNODEFICIENCY-VIRUS, SYNCYTIUM-INDUCING PHENOTYPE, INFECTED PATIENTS, DISEASE PROGRESSION, EXPERIENCED PATIENTS

Downloads

  • Mortier 2013 PLoSOne.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.18 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Mortier, Virginie, Kenny Dauwe, Leen Vancoillie, Delfien Staelens, Filip Van Wanzeele, Dirk Vogelaers, Linos Vandekerckhove, Kristen Chalmet, and Chris Verhofstede. 2013. “Frequency and Predictors of HIV-1 Co-receptor Switch in Treatment Naive Patients.” Plos One 8 (11).
APA
Mortier, V., Dauwe, K., Vancoillie, L., Staelens, D., Van Wanzeele, F., Vogelaers, D., Vandekerckhove, L., et al. (2013). Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients. PLOS ONE, 8(11).
Vancouver
1.
Mortier V, Dauwe K, Vancoillie L, Staelens D, Van Wanzeele F, Vogelaers D, et al. Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients. PLOS ONE. 2013;8(11).
MLA
Mortier, Virginie et al. “Frequency and Predictors of HIV-1 Co-receptor Switch in Treatment Naive Patients.” PLOS ONE 8.11 (2013): n. pag. Print.
@article{3230011,
  abstract     = {Background: Determination of HIV-1 co-receptor use is a necessity before initiation of a CCR5 antagonist but the longevity of a CCR5-use prediction remains unknown.
Methods: Genotypic co-receptor tropism determination was performed in 225 newly diagnosed individuals consulting an AIDS Reference Centre. Samples were collected at diagnosis and at initiation of antiretroviral therapy or just before closure of the study for patients who did not initiate therapy. For individuals with a discordant tropism prediction on the two longitudinal samples, analysis of intermediate samples and single genome sequencing of proviral DNA was performed to confirm the tropism switch. Deep sequencing was done to identify minor CXCR4 or CCR5-using populations in the initial sample.
Results: Overall, tropism switches were rare (7.6%). Only a geno2pheno false positive rate of <50% at baseline was retained as predictive for a subsequent switch from CCR5-use only to predicted CXCR4-use. Minor CXCR4-using virus populations were detected in the first sample of 9 of the 14 R5-to-X4 switchers but the subsequent outgrowth of these minor populations was documented in only 3.
Conclusions: With the current guidelines for treatment initiation at CD4(+) T cell counts of <500 cells/mm(3), co-receptor switch between diagnosis and starting antiretroviral therapy is rare. Patients with R5 viruses and a geno2pheno FPR of <50% are more prone to subsequent co-receptor switch than patients with an FPR of >50% and will need repeat tropism testing if initiation of maraviroc is considered and previous testing dates from more than a year before.},
  articleno    = {e80259},
  author       = {Mortier, Virginie and Dauwe, Kenny and Vancoillie, Leen and Staelens, Delfien and Van Wanzeele, Filip and Vogelaers, Dirk and Vandekerckhove, Linos and Chalmet, Kristen and Verhofstede, Chris},
  issn         = {1932-6203},
  journal      = {PLOS ONE},
  keywords     = {TROPISM,PROGNOSTIC VALUE,USAGE,AIDS,INTERACTIVE TREE,HUMAN-IMMUNODEFICIENCY-VIRUS,SYNCYTIUM-INDUCING PHENOTYPE,INFECTED PATIENTS,DISEASE PROGRESSION,EXPERIENCED PATIENTS},
  language     = {eng},
  number       = {11},
  pages        = {9},
  title        = {Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients},
  url          = {http://dx.doi.org/10.1371/journal.pone.0080259},
  volume       = {8},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: